ArticlePediatric cardiology2011
Engineered human cardiac tissue.
Article in Pediatric cardiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Modulating hESC-derived cardiomyocyte and endothelial cell function with triple-helical peptides for heart tissue engineering.Biomaterials · 2021Article
- Artificial Cardiac Muscle with or without the Use of Scaffolds.BioMed research international · 2017Review
- Chronic High-Fat Feeding Affects the Mesenchymal Cell Population Expanded From Adipose Tissue but Not Cardiac Atria.Stem cells translational medicine · 2015Article
- Anisotropic silk biomaterials containing cardiac extracellular matrix for cardiac tissue engineering.Biomedical materials (Bristol, England) · 2015Article
- Clinical applications of naturally derived biopolymer-based scaffolds for regenerative medicine.Annals of biomedical engineering · 2015Review
- Heart regeneration with engineered myocardial tissue.Annual review of biomedical engineering · 2014Review
- New mechanistic and therapeutic targets for pediatric heart failure: report from a National Heart, Lung, and Blood Institute working group.Circulation · 2014Article
- Pluripotent stem cell derived cardiomyocytes for cardiac repair.Current treatment options in cardiovascular medicine · 2014Article
- Induced pluripotent stem cells for post-myocardial infarction repair: remarkable opportunities and challenges.Circulation research · 2014Review
- A tunable silk-alginate hydrogel scaffold for stem cell culture and transplantation.Biomaterials · 2014Article
- Gene expression profiles in engineered cardiac tissues respond to mechanical loading and inhibition of tyrosine kinases.Physiological reports · 2013Article
- Engineered Human Muscle Tissue from Skeletal Muscle Derived Stem Cells and Induced Pluripotent Stem Cell Derived Cardiac Cells.International journal of tissue engineering · 2013Article
- A novel suture-based method for efficient transplantation of stem cells.Journal of biomedical materials research. Part A · 2013Article
- Stem cell-based cardiac tissue engineering.Journal of cardiovascular translational research · 2011Review
- Strategies for tissue engineering cardiac constructs to affect functional repair following myocardial infarction.Journal of cardiovascular translational research · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The human heart is the first organ to develop during embryogenesis and is arguably the most essential organ for life. However, after birth, the heart has very little capacity to repair malformations such as congenital heart defects or to regenerate after an injury such as myocardial infarction. Cardiac tissue engineering addresses the need for a therapeutic biologic implant to restore cardiac structure and muscle mass. This review highlights current research in cardiac tissue engineering that uses human cardiomyocytes derived from embryonic stem cells. Other human cell sources are discussed because future human therapies will benefit from novel techniques using human-induced pluripotent stem cells and cardiomyocytes derived from direct reprogramming of somatic cells. Furthermore, this review examines the main approaches to creating engineered cardiac tissue with synthetic scaffolds, natural scaffolds, or no exogenous scaffold (i.e., "scaffold free"). The choice of scaffold and cells ultimately depends on the goals of the therapy, so the review considers how congenital heart defects define the design parameters for cardiac tissue engineering needed for surgical repair in pediatric cardiac patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.